Meth/amphetamine and other stimulants

Key findings

More information is available in the Meth/amphetamine and other stimulants fact sheet.

Stimulants are a group of drugs that produce stimulatory effects by increasing nerve transmission in the brain and body (Nielsen & Gisev 2017). Included in this group are:

  • Amphetamines used for therapeutic purposes to treat attention deficit-hyperactivity disorder (ADHD), but may also be used non-medically. 
  • Methamphetamine (also referred to as methylamphetamine) – a potent derivative of amphetamine that is commonly found in 3 forms: powder (speed), base and its most potent form, crystalline (ice or crystal). Due to slight structural differences, methamphetamine produces a stronger nervous system response than amphetamine (ACIC 2019a).
  • 3, 4-methylenedioxymethamphetmine (MDMA)—commonly referred to as ‘ecstasy’— is an amphetamine derivative. (Note ecstasy may contain a range of other drugs and substances and may contain no MDMA at all).
  • Cocaine – produced from a naturally occurring alkaloid found in the coca plant.

The focus in this section is on the illicit use of meth/amphetamine and other stimulants (Box STIM1).

Box STIM1: Defining amphetamines and other stimulants

Data sources on methamphetamine, amphetamine and other psychostimulants contain a variety of terms; in some instances these terms cover similar, but not the same range of drugs. This can be confusing when interpreting results across different data sources.

In this section, the terminology used reflects that adopted in the corresponding data source. Below is a description of each term used in these data sources and the types of drugs they encompass:

  • Amphetamine-type stimulants (ATS)—covers a large range of drugs, which includes amphetamine, methylamphetamine and phenethylamines (a class of drug that includes MDMA or ‘ecstasy’).
  • Amphetamines—refers to a broad category of substances. According to the Australian Standard Classification of Drugs of Concern (ASCDC) (ABS 2011), this includes amphetamine, methylamphetamine, dexamphetamine, amphetamine analogues and amphetamines not elsewhere classified. This is the term used in the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS).
  • Methamphetamine (also methylamphetamine) also comes in different forms, including powder/pills (speed), crystal methylamphetamine (crystal meth or ice), a sticky paste (base), and a liquid form.
  • Meth/amphetamine includes methylamphetamine and amphetamine and is the term used in the National Drug Strategy Household Survey (NDSHS).
  • Ecstasy (also MDMA) is often consumed in the form of a tablet, but can also be in powder or crystal form.
  • Cocaine is commonly consumed in powder form, which can be snorted or dissolved in water so it can be injected.
  • Psychostimulants (also stimulants) includes ecstasy, methamphetamine, cocaine and new psychoactive substances (NPS). This is the sampling criteria for participants of the Ecstasy and related Drugs Reporting System (EDRS).

Availability

Methamphetamine and other stimulants are readily available in Australia. Findings from the 2019 Illicit Drug Reporting System (IDRS) showed that the majority of people who inject drugs and use meth/amphetamine or cocaine report that it is ‘easy’ or ‘very easy’ to obtain (Peacock et al. 2019b) (Table S2.6). Similar findings from the 2019 Ecstasy and Related Drugs Reporting System (EDRS) also show that the majority of people who use ecstasy and other stimulants report that meth/amphetamine, ecstasy and cocaine are ‘easy’ or ‘very easy’ to obtain (Peacock et al. 2019a).

Perceived availability was the highest for crystal methamphetamine (95% of IDRS and 94% of EDRS users rated it ‘easy or very easy’ to obtain), while perceived availability for other forms of methamphetamine was lower. Perceived availability of ecstasy in all forms has declined over the last 3 years, with the highest availability reported for capsules (92% of EDRS users rated it ‘easy’ or ‘very easy’ to obtain), followed by pill (81%), crystal (81%) and powder (76%) forms (Peacock et al. 2019b). Cocaine was rated ‘easy’ or ‘very easy’ to obtain by 62% of IDRS users and 70% of EDRS users (Peacock et al. 2019a; Peacock et al. 2019b).

In 2019, the main approach for arranging the purchase of illicit or non-prescribed drugs by EDRS users in the previous 12 months was via social networking applications (such as Facebook, WhatsApp, SnapChat, Grindr, Tinder) (43%), followed by face-to-face (34%) (Peacock et al. 2019a). In 2017–18, nearly a third of national illicit drug seizures (32.9%) and arrests (30.3%) were for ATS (including MDMA) (ACIC 2019a). The number of national ATS arrests in 2017–18 was 44,887, an increase of 173% from the 16,452 arrests reported in 2008–09 (ACIC 2019a; ACC 2010). The number of national ATS seizures has increased by 179% over the last decade, with 37,093 seizures in 2017–18, up from 13,300 in 2008–09. In 2017–18, ATS made up 36.6% of the total weight of illicit drugs seized nationally. The total weight of ATS seized nationally has also increased by 583% over the last decade, from 1,640.2 kilograms in 2008–09 to 11,205 kilograms in 2017–18, the second highest weight on record (ACIC 2019a; ACC 2010).

Methamphetamine is domestically produced, with considerable quantities of the drug also detected at the Australian border (ACC 2015). In 2017–18, there were 2,451 amphetamine-type stimulant (excluding MDMA) detections at the Australian border, weighing 2,952.4 kilograms. The 31,204 national amphetamines seizures in 2017–18 weighed 5,064.9 kilograms and accounted for 84.1% of the number and 45.2% of the weight of national ATS seizures this reporting period (ACIC 2019a). Recent research (ACIC 2019b) has shown the impact of seizures on consumption—see Supply reduction– Prohibited substances.

The number of MDMA (ecstasy) detections at the Australian border was 3,530 in 2017–18, while the weight of MDMA detections was 1,420.8 kilograms. The number of national MDMA seizures was 5,719 in 2017–18, and the total weight of MDMA seized nationally was 2,033.0 kilograms, accounting for 18.1% of all ATS seized nationally (ACIC 2019a).

Over the last decade, the number of cocaine detections at the Australian border increased by 664%, from 359 in 2008–09 to 2,741 in 2017–18. The weight of cocaine detected has also increased by 83%, from 506 kilograms in 2008–09 to 926.5 kilograms in 2017–18 (ACIC 2019a; ACC 2010).

The number of national cocaine seizures has increased by 319% over the last decade, from 1,217 in 2008–09 to 5,096 seizures in 2017–18. The total weight of cocaine seized nationally increased by 233% over the same period, from 591.9 kilograms in 2008–09 to 1,970.7 kilograms in 2017–18, the second highest weight on record (ACIC 2019a; ACC 2010). The number of national cocaine arrests has also increased by 410% over the past decade, from 848 in 2008–09 to a record 4,325 in 2017–18 (ACIC 2019a; ACC 2010).

Consumption

There are differences in trends and patterns of consumption in Australia according to the type of stimulant used.

Meth/amphetamine

  • 1.4% of people aged 14 and over in Australia reported using meth/amphetamine in the last 12 months (Figure STIM1).
  • Aboriginal and Torres Strait Islander people are 2.2 times more likely to use methamphetamine than non-Indigenous Australians (AIHW 2017).
  • 33% of regular ecstasy and other stimulant users reported use of any form of methamphetamine in the previous 6 months (Peacock et al. 2019b).
  • 78% of people who inject drugs reported use of any form of meth/amphetamine in the previous 6 months (Peacock et al. 2019b).

Self-reported data on methamphetamine consumption in the general Australian population has been declining since it peaked at 3.4% in 2001. There was also a significant decline between 2013 and 2016, from 2.1% to 1.4%. This decline was mainly driven by a substantial decrease among people aged in their 20s, whereby recent use of meth/amphetamine halved among this age group between 2013 and 2016 for both males and females (AIHW 2017) (Table S2.44).

In 2013, there was a change in the main form of methamphetamine used by the general population, with ‘ice’ replacing powder as the preferred form of the drug. In 2016, this trend continued with 57% of meth/amphetamine users reporting that crystal/ice was the main form used in the previous 12 months, up from 50% in 2013 (AIHW 2017). Over the same period, use of powder significantly decreased. While overall recent meth/amphetamine use declined between 2013 and 2016, the proportion of the total population using crystal/ice remained relatively stable between 2013 and 2016 and has increased since 2010 (AIHW 2017).

Surveys of regular ecstasy and other stimulant users also showed the use of crystal methamphetamine was relatively stable between 2013 and 2016. However, the use of crystal methamphetamine declined between 2016 and 2017 (from 19% to 13%). This was followed by an increase in 2018 (17%) and 2019 (18%), returning the proportion to levels similar to those reported in 2016 (Peacock et al. 2019a) (Table S2.49).

According to the Drug Use Monitoring in Australia (DUMA) program, in 2018, 54% of police detainees tested positive to amphetamines (Voce & Sullivan 2019). Of the detainees testing positive for any amphetamine, the majority (96%) tested positive for methamphetamine (52% of detainees, overall) (Voce & Sullivan 2019). The proportion of detainees testing positive to methamphetamine increased from 46% in 2017 (Patterson et al. 2019) to 52% in 2018 (Voce & Sullivan 2019).

In 2018, the proportion of detainees testing positive to methamphetamine (52%) was higher than the proportion of those testing positive to cannabis (47%) (Voce & Sullivan 2019).

In 2018, the majority of detainees whose most serious offence was property related tested positive to amphetamines (68%), as did most drug (62%) and traffic offenders (50%) (Voce & Sullivan 2019).

Of Australia’s prison entrants in 2018, 65% had used illicit drugs in the last 12 months with the most common drug being methamphetamine (43%) (AIHW 2019c).

Ecstasy

  • 2.2% of people aged 14 and over in Australia used ecstasy in the previous 12 months (Figure STIM1).
  • The prevalence in recent ecstasy use in 2016 was higher in males (2.6% compared with females 1.8%).
  • Between 2010 and 2016, recent use of ecstasy has generally declined across Australia (3.0% in 2010 to 2.2% in 2016).
  • Ecstasy and cannabis were the most common reported drug of choice for participants of the EDRS who are regular ecstasy and other stimulant users (Peacock et al. 2019b).

Between 2013 and 2016, lifetime use of ecstasy increased for people in their 40s (from 11.8% to 14.8%) and 50s (from 1.7% to 2.4%), but decreased for people in their 20s (from 22.1% to 18.7%) (AIHW 2017) (Table S2.45). Recent ecstasy use has been declining since peaking in 2007. Since 2001, recent use has generally decreased among the younger age group but remained similar over the same period for people aged 30 and over (AIHW 2017) (Table S2.46).

In 2018, 1% of police detainees tested positive to MDMA (Table S3.59), equal to the proportion reported in 2017 (Patterson et al. 2019). Since DUMA commenced in 1999, the number of detainees testing positive to MDMA has remained low—under 3% (Patterson et al. 2018).

Cocaine

  • 2.5% of people aged 14 and over in Australia used cocaine in the last 12 months (AIHW 2017).
  • The prevalence in recent cocaine use in 2016 was higher in males (3.1%) than females (2.0%).
  • 13% of injecting drug users used cocaine in the last 6 months (Peacock et al. 2019b).
  • 67% of regular ecstasy and other stimulant users used cocaine in the last 6 months (Peacock et al. 2019a).

According to the NDSHS, the proportion of people aged 14 and over using cocaine has been increasing in Australia since 2004. Between 2001 and 2016, lifetime cocaine use increased across all age groups except for those aged 14–19, and significantly increased between 2013 and 2016 for people in their 30s and 40s (Table S2.47).

Cocaine use is infrequently reported among people who inject drugs, with only 13% reporting use at least once in the last 6 months (Peacock et al. 2019b). For participants of the EDRS, cocaine was the third most commonly used stimulant drug (after ecstasy and cannabis) with 67% reporting recent use in 2019, the highest percentage of participants in the study’s history (Peacock et al. 2019a) (Table S2.49).

Data from the DUMA program showed that the proportion of police detainees testing positive to cocaine has remained stable at 2% in 2017 and 2018 (Voce & Sullivan 2019).

Geographic trends

Recent data from the National Wastewater Drug Monitoring Program (NWDMP) shows that:

  • Methamphetamine remains the highest consumed illicit drug monitored by the program (for substances that have available dose data), with the estimated regional average consumption of methamphetamine continuing to exceed estimated capital city average consumption. In April 2019, average methamphetamine consumption for both regional and capital city sites increased to its highest levels recorded by the program. Between April 2019 and August 2019, average methamphetamine consumption decreased in both regional and capital city sites.
  • In comparison with other illicit drugs monitored by the program, the estimated consumption of MDMA was low across the country, with the regional average consumption of MDMA similar to capital city average consumption. This is in contrast to historical data where regional averages tended to be higher than the capital cities. In April 2019, the regional and capital city average consumption of MDMA increased to its highest levels since the beginning of the program. However, between April 2019 and August 2019, average MDMA consumption decreased in both regional and capital city sites.
  • The capital city average consumption of cocaine was higher than the regional average. In April 2019, average cocaine consumption for both regional and capital city sites increased to its highest levels recorded by the program. However, between April 2019 and August 2019, average cocaine consumption decreased in both regional and capital city sites (ACIC 2020).

It is important to note that the NWDMP does not measure all drug types.

Data from the 2016 NDSHS showed that:

  • Recent use of meth/amphetamine declined between 2013 and 2016 across all states and territories, with the highest proportion of recent use in 2016 reported in Western Australia (2.7%) (Table S2.48).
  • People living in Remote and very remote areas were 2.5 times more likely than those from Major cities to have used methamphetamine in 2016 (3.5% compared with 1.4%). Similarly, those living in the lowest socioeconomic areas were twice as likely to have used meth/amphetamine as those living in the highest socioeconomic areas (1.8% compared with 0.9%) (Figure STIM2).
  • NSW recorded the highest recent use of cocaine (3.4%).
  • Cocaine use was most prevalent among those who were employed and lived in Major cities or the highest socioeconomic areas (AIHW 2017).
  • Western Australia recorded the highest proportion of recent use of ecstasy in 2016 (3.2%), overtaking the Northern Territory (AIHW 2017) (Table S2.48).

Explore state and territory data on the use of methamphetamine and other stimulants in Australia.

Harms

The short and long-term effects associated with the use of methamphetamine and other stimulants are provided in Table STIM1. 

Table STIM1: Short and long-term effects associated with the use of methamphetamine and other stimulants

Drug type

Short-term effects

Long-term effects

Methamphetamine (includes powder, base and crystal/ice)

  • Increased energy
  • Sense of euphoria and wellbeing
  • Increased attention and alertness
  • Increased talkativeness
  • Increased heart rate, breathing and body temperature
  • Decreased appetite
  • Jaw clenching and teeth grinding
  • Nausea and vomiting
  • A dry mouth
  • Changes in libido
  • Nervousness, anxiety and paranoia
  • Aggression and violence
  • Mood and anxiety disorders
  • Cardiovascular problems
  • Haemorrhagic stroke
  • Poor concentration and memory
  • Psychotic symptoms such as paranoia and hallucinations
  • Weight loss
  • Chest pains

Ecstasy/MDMA

  • Sense of euphoria and wellbeing
  • Feelings of intimacy with others
  • Confidence
  • Lack of inhibitions
  • Nausea
  • Sweating
  • Increased blood pressure and pulse rate
  • Jaw clenching and teeth grinding
  • Depression
  • Anxiety
  • Memory and cognitive impairment

Cocaine

  • Sense of euphoria and wellbeing
  • Increased blood pressure, heart rate and body temperature
  • Increased alertness and energy
  • Sexual arousal
  • Loss of appetite
  • Sleep disorders
  • Sexual problems such as impotence
  • Nose bleeds, sinusitis and damage to the nasal wall from snorting
  • Cardiovascular problems
  • Stroke
  • Paranoia, depression and anxiety
  • Cocaine-induced psychosis

Source: Adapted from ACIC 2019a; Darke, Kaye & Duflou 2017; NSW Ministry of Health 2017.

Burden of disease and injury

Amphetamine use was responsible for 0.6% of the total burden of disease and injuries in Australia in 2015 and 21% of the total burden due to illicit drug use (AIHW 2019b) (Table S2.69).

Of the burden due to amphetamine use, drug use disorder (excluding alcohol) contributed 28%, poisoning 5% and suicide and self-inflicted injuries 4.3%. Other contributors to the burden due to amphetamine use included road traffic injuries—motorcyclists (3.2%) and road traffic injuries—motor vehicle occupants (2.5%) (AIHW 2019b).

Cocaine use contributed 0.3% of the total burden of disease and injuries in 2015 and 11.4% of the total burden due to illicit drug use (Table S2.69). Of the burden due to cocaine use, suicide and self-inflicted injuries accounted for 6.2% and drug use disorder (excluding alcohol) 11% (AIHW 2019b).

Hospitalisations

According to information drawn from the National Hospital Morbidity Database, 7.6% of all drug-related hospital separations in 2017-18 were reported with a principal drug of methamphetamine. This is a notable increase from 3.1% of all drug-related hospital separations in 2013-14.

The rate of drug-related hospital separations for methampetamines was higher for people usually residing in Major cities (41.1 per 100,000 population) compared with Regional and remote areas (31.8 per 100,000 population) (Table S1.8c).

Mental health

The consumption of meth/amphetamine and other stimulants can be associated with considerable negative impact on mental health and this appears to be increasing.

The NDSHS found a statistically significant increase from 2013 to 2016 in the proportion of people who used meth/amphetamine (from 29% to 42%), ecstasy (from 17.9% to 27%) and cocaine (from 17.4% to 25%) in the previous 12 months reporting mental illness (Figure STIM3; Table S2.73).

There were also significant increases in the proportion of meth/amphetamine and ecstasy users who report ‘high to very high’ levels of psychological distress (AIHW 2017) (Table S2.72). 

Deaths

The number of drug-induced deaths related to methamphetamine and other stimulants (including amphetamines, methamphetamine, ecstasy/MDMA and caffeine) in Australia has increased at a fast rate, with the death rate in 2018 4 times higher than that in 1999 (1.7 deaths compared with 0.4 deaths per 100,000 population, respectively) (Table S1.1). Over the same period, the rate of drug-induced deaths involving cocaine increased from 0.1 deaths to 0.2 deaths per 100,000 population (Table S1.1).

The National Drug and Alcohol Research Centre (NDARC) reported that in 2018 there were 99 amphetamine-induced deaths in Australia—a rate of 0.4 per 100,000 people (Man et al. 2019). There were also fewer than 20 cocaine-induced deaths in Australia in 2018—consistent with previous years (Man et al. 2019).

Recent research examining methamphetamine-related deaths in isolation from other stimulants, found that mortality rates have almost doubled during a period of 7-years between 2009 and 2015. The most common manner of methamphetamine-related death was accidental drug toxicity; however, natural disease (e.g. coronary disease, stroke, kidney disease, and liver disease), suicide and accident comprised more than half of the deaths (Darke, Kaye & Duflou 2017).

Treatment

Amphetamines

Data from the AIHW Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS NMDS) for amphetamines correspond to the Australian Standard Classification of Drugs of Concern (ASCDC) code for the general ‘amphetamines’ classification, in which methamphetamine is a sub-classification. Specific coding for methamphetamine episodes have not previously been available due to the nature of the coding structure. This has improved over time, due to improved workforce training and new system updates (AIHW 2020).

The AODTS NMDS showed that in 2018–19:

  • Amphetamines were a principal drug of concern for a client’s own drug use in 28% of closed treatment episodes, the second most common principal drug of concern behind alcohol (36%) (Figure STIM4).
  • Of the 28% of closed treatment episodes where amphetamines were reported as a principal drug of concern, two-thirds (66%) were for methamphetamines.
  • Client demographics where amphetamines were a principal drug of concern:
    •  Almost two-thirds of clients were male (65%) (Table S2.77) and about 1 in 6 clients were Indigenous (17.0%) (Table S2.78).
  • Source of referral for treatment:
    • The most common source of referral for treatment with amphetamines as the principal drug of concern was self/family (38% of treatment episodes), followed by health services (25%) and diversion (12.7%) (Table S2.79).
  • Treatment type:
    • The most common main treatment type  with amphetamines as the principal drug of concern was counselling (41% of treatment episodes), followed by assessment only (22%) and support and case management only (10.4%) (Table S2.80).

Where the principal drug of concern was amphetamines, the proportion of people living in Regional and remote areas who travelled 1 hour or longer to treatment services was higher than in Major cities (31% compared with 10%) (AIHW 2019a). 

Visualisation not available for printing

Ecstasy

  • Ecstasy was a principal drug of concern for a client’s own drug use in 0.6% of closed treatment episodes in 2018–19 (Table S2.76).
  • Client demographics where ecstasy was a principal drug of concern:
    •  Almost 8 in 10 (79% of clients) were male (Table S2.77) and 4.9% were Indigenous (Table S2.78).
  • Source of referral for treatment:
    • In over half  (58%) of treatment episodes where ecstasy was the principal drug of concern, the client’s source of referral was diversion (Table S2.80).
  • Treatment type:
    • The most common main treatment type for episodes where ecstasy was the principal drug of concern was information and education only (44%), followed by counselling (25%) and assessment only (16.8%) (Table S2.80).

Cocaine

  • Cocaine was a principal drug of concern for a client’s own drug use in 0.8% of closed treatment episodes in 2018–19 (Table S2.76).
  • Client demographics where cocaine was a principal drug of concern:
    •  88% of clients were male (Table S2.77) and 4.3% were Indigenous (Table S2.78).
  • Source of referral for treatment:
    • In almost 2 in 5 (38%) treatment episodes where cocaine was the principal drug of concern, the client’s source of referral was from self/family. Diversion was the source of referral in 25% of treatment episodes for cocaine (Table S2.79). 
  • Treatment type:
    • The most common main treatment type where cocaine was the principal drug of concern was counselling (42% of episodes), followed by assessment only (22%) (AIHW 2020) (Table S2.80).

Policy context

Public perceptions and policy support

The NDSHS found that between 2013 and 2016, people’s perceptions of meth/amphetamine changed considerably. More people associated it with a drug problem (22% compared with 46%), thought it caused the most deaths (8.7% compared with 19%) and thought it was the drug of most concern to the community (16% compared with 40%) (tables S2.36, S2.37 and S2.70). It is possible that these self-report surveys underestimate the true extent of meth/amphetamine use, particularly in the context of the stigmas that exist around its consumption (AIHW 2017).

National Ice Action Strategy 2015

In April 2015, the Australian Government established a National Ice Taskforce, to provide advice on the development of a National Ice Action Strategy (NIAS).

The objectives of the NIAS are to ensure that:

  • families and communities have better access to information, support and tools to help them to respond to ice (methamphetamine);
  • prevention messages are targeted at high-risk populations and accurate information about ice is more accessible;
  • early intervention and treatment services are better tailored to respond to ice and meet the needs of the populations they serve;
  • law enforcement efforts are better targeted to disrupt the supply of ice; and
  • better evidence is available to drive responses to the effects of ice in our community (DoH 2017).

Resources and further information

References

ACC (Australian Crime Commission) 2010. Illicit Drug Data Report 2008–09. Canberra: ACIC. Viewed 7 August 2019.

ACC 2015. The Australian methylamphetamine market: the national picture. Canberra: ACC. Viewed 24 November 2017.

ACIC (Australian Criminal Intelligence Commission) 2019a. Illicit Drug Data Report 2017–18. Canberra: ACIC. Viewed 7 August 2019.

ACIC 2019b. Methylamphetamine supply reduction—measures of effectiveness. Canberra: ACIC. Viewed 14 October 2019.

ACIC 2020. National Wastewater Drug Monitoring Program Report 9, 2020. Canberra: ACIC. Viewed 2 April 2020.

AIHW (Australian Institute of Health and Welfare) 2017. National Drug Strategy Household Survey 2016: detailed findings. Drug statistics series no. 31. Cat. no. PHE 214. Canberra: AIHW. Viewed 14 December 2017.

AIHW 2019a. Alcohol and other drug use in regional and remote Australia: consumption, harms and access to treatment, 2016–17. Cat. no. HSE 212. Canberra: AIHW. Viewed 15 March 2019.

AIHW 2019b. Australian burden of disease study: Impact and causes of illness and death in Australia 2015. Series no.19. BOD 22. Canberra: AIHW. Viewed 13 June 2019.

AIHW 2019c. The health of Australia’s prisoners 2018. Cat. no. PHE 246. Canberra: AIHW. Viewed 30 May 2018.

AIHW 2020. Alcohol and other drug treatment services in Australia 2018–19. Cat. no. HSE 243. Canberra: AIHW. Viewed 26 June 2020.

Darke S, Kaye S & Duflou J 2017. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction 112: 2191-2201.

DoH (Department of Health) 2017. National ice action strategy. Canberra: DoH. Viewed 29 November 2017.

Man N, Chrzanowska A,  Dobbins T, Degenhardt L & Peacock A 2019. Trends in drug-induced deaths in Australia, 1997-2018. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Viewed 8 January 2020.

Nielsen S & Gisev N 2017. Drug pharmacology and pharmacotherapy treatments. In Ritter, King and Lee (eds). Drug use in Australian society. 2nd edn. Oxford University Press.

NSW Ministry of Health 2017. A quick guide to drugs & alcohol, 3rd edn. Sydney: National Drug and Alcohol Research Centre UNSW.

Patterson E, Sullivan T, Ticehurst A & Bricknell S 2018. Drug use monitoring in Australia: 2015 and 2016 report on drug use among police detainees. Statistical Reports Number 4. Canberra: Australian Institute of Criminology. Viewed 8 January 2020.

Patterson E, Sullivan T & Bricknell S 2019. Drug use monitoring in Australia: Drug use among police detainees, 2017, Statistical Reports Number 14. Canberra: Australian Institute of Criminology. Viewed 8 January 2020.

Peacock A, Karlsson A, Uporova J, Gibbs D,  Swanton R, Kelly G, Price O, Bruno R, Dietze P, Lenton S,  Salom C, Degenhardt L, & Farrell, M 2019b. Australian Drug Trends 2019: Key findings from the National Ecstasy and Related Drugs Reporting System (EDRS) Interviews. Sydney: National Drug and Alcohol Research Centre UNSW.

Peacock A, Uporova J, Karlsson A, Gibbs D, Swanton R,  Kelly G, Price O, Bruno R, Dietze P, Lenton S, Degenhardt L & Farrell M 2019a. Australian Drug Trends 2019: Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney: National Drug and Alcohol Research Centre UNSW.

Voce A & Sullivan T 2019. Drug use monitoring in Australia: Drug use among police detainees, 2018. Statistical Reports no. 18. Canberra: Australian Institute of Criminology. Viewed 8 January 2020.